Receptor TrK
Os inibidores dos receptores Trk têm como alvo as quinases receptoras da tropomiosina (Trk), uma família de tirosina quinases receptoras que desempenham um papel significativo no desenvolvimento e função do sistema nervoso. Os receptores Trk estão envolvidos na sinalização de neurotrofinas, essencial para a sobrevivência, diferenciação e crescimento dos neurônios. A desregulação da sinalização Trk está associada a distúrbios neurológicos e certos tipos de câncer. Na CymitQuimica, oferecemos inibidores dos receptores Trk para apoiar sua pesquisa em neurobiologia, oncologia e doenças neurodegenerativas.
Foram encontrados 59 produtos de "Receptor TrK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Amitriptyline hydrochloride
CAS:<p>Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive</p>Fórmula:C20H24ClNPureza:97% - 99.94%Cor e Forma:Crystals White To Off-White PowderPeso molecular:313.86CE-245677
CAS:<p>CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.</p>Fórmula:C24H22Cl2N6O3Pureza:98.99% - 99.23%Cor e Forma:SolidPeso molecular:513.38N-Acetyl-5-hydroxytryptamine
CAS:<p>N-Acetyl-5-hydroxytryptamine, or Normelatonin, is melatonin's precursor, made from serotonin, and activates TrkB receptor.</p>Fórmula:C12H14N2O2Pureza:98.31% - 99.91%Cor e Forma:SolidPeso molecular:218.25CRB-0089
<p>CRB-0089 is a human monoclonal antibody targeting NGF/bNGF. It is used in the study of analgesia.</p>Cor e Forma:Odour LiquidAnti-TrkB/NTRK2 Antibody
<p>Anti-TrkB/NTRK2 Antibody is a human-derived antibody produced in CHO cells, targeting TrkB. For the isotype control of Anti-TrkB/NTRK2 Antibody, refer to HumanIgG2kappa, Isotype Control.</p>Cor e Forma:Odour LiquidAdimanebart
CAS:<p>Amdokitug is a human-derived IgG1λ monoclonal antibody that acts as an inhibitor of MUSK.</p>Cor e Forma:LiquidTrkA-IN-6
<p>TrkA-IN-6 (compound R48) is a hydrazone-based, selective inhibitor of the tropomyosin receptor kinase A (TrkA). It exhibits greater cytotoxicity towards U87 GBM cells compared to Temozolomide, with an IC50 of 68.99 μM.</p>Fórmula:C16H13N3O5Peso molecular:327.08552GNF-8625 monopyridin-N-piperazine hydrochloride
CAS:<p>GNF-8625 monopyridin-N-piperazine hydrochloride is a protomyosin receptor kinase (TRK) inhibitor.</p>Fórmula:C25H27ClFN7Pureza:98.97%Cor e Forma:SolidPeso molecular:479.98Protein kinase inhibitor 5 sulfate hydrate
<p>Protein kinase inhibitor 5 sulfate hydrate, a potent TRK-A inhibitor, exhibits an IC50 of 1.8 nM and impairs cell viability [1].</p>Fórmula:C29H35F2N7O6SPureza:98%Cor e Forma:SolidPeso molecular:647.69PF-06737007
CAS:<p>PF-06737007 is an effective inhibitor of pan-Trk in cell-based assays (IC50s: 7.7 nM, 15 nM, and 3.9 nM for TrkA, TrkB, and TrkC, respectively).</p>Fórmula:C25H28F4N2O6Pureza:98%Cor e Forma:SolidPeso molecular:528.49Selitrectinib
CAS:<p>Selitrectinib (LOXO-195) is a potent and selective inhibitor of the receptor tyrosine kinases(TRK).Cost-effective and quality-assured.</p>Fórmula:C20H21FN6OPureza:99.55% - ≥95%Cor e Forma:SolidPeso molecular:380.42ONO-7475
CAS:<p>ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase</p>Fórmula:C32H26N4O6Pureza:98.74%Cor e Forma:SolidPeso molecular:562.57Entrectinib
CAS:<p>Entrectinib (RXDX-101) is an orally Trk, ROS1, and ALK inhibitor. Entrectinib exhibits antitumor activity. Cost-effective and quality-assured.</p>Fórmula:C31H34F2N6O2Pureza:98.03% - 99.61%Cor e Forma:SolidPeso molecular:560.64Milciclib
CAS:<p>Milciclib (PHA-848125) is a potent CDK2 inhibitor with a 45 nM IC50, selective over CDK1/2/4/5/7. In Phase 2 trials.</p>Fórmula:C25H32N8OPureza:99.28%Cor e Forma:SolidPeso molecular:460.57LM22A-4
CAS:<p>LM22A-4: BDNF mimetic, TrkB agonist, IC50=47 nM (fluorescence anisotropy).</p>Fórmula:C15H21N3O6Pureza:99.56%Cor e Forma:SolidPeso molecular:339.34Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46Ensartinib hydrochloride
CAS:<p>Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known</p>Fórmula:C26H29Cl4FN6O3Pureza:98.73%Cor e Forma:SolidPeso molecular:634.36Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Fórmula:C33H44FN5O3Pureza:99.33% - 99.44%Cor e Forma:SolidPeso molecular:577.73ANA-12
CAS:<p>ANA-12 is a potent and selective TrkB antagonist with anxiolytic and antidepressant activity in mice.</p>Fórmula:C22H21N3O3SPureza:99.28% - 99.87%Cor e Forma:SolidPeso molecular:407.49LOXO-195
CAS:<p>(6RS)-LOXO-195 (BAY 2731954) is a potent and selective Trk tyrosine kinase inhibitor.</p>Fórmula:C20H21FN6OPureza:99.54%Cor e Forma:SolidPeso molecular:380.42GNF-5837
CAS:<p>GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA/TrkB (IC50: 8/12 nM).</p>Fórmula:C28H21F4N5O2Pureza:97.26% - 98.08%Cor e Forma:SolidPeso molecular:535.49DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8GW 441756
CAS:<p>GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.</p>Fórmula:C17H13N3OPureza:97.73% - 99.8%Cor e Forma:SolidPeso molecular:275.3Tyrphostin AG 879
CAS:<p>Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.</p>Fórmula:C18H24N2OSPureza:99.05%Cor e Forma:SolidPeso molecular:316.46Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Fórmula:C33H29F2N5O4SPureza:98.9% - 99.85%Cor e Forma:SolidPeso molecular:629.68LM22B-10
CAS:<p>LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.</p>Fórmula:C27H33ClN2O4Pureza:98.18%Cor e Forma:SolidPeso molecular:485.01Larotrectinib
CAS:<p>Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).</p>Fórmula:C21H22F2N6O2Pureza:99.15% - >99.99%Cor e Forma:SolidPeso molecular:428.44CH7057288
CAS:<p>CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.</p>Fórmula:C32H31N3O5SPureza:99.92%Cor e Forma:SolidPeso molecular:569.67Larotrectinib sulfate
CAS:<p>Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).</p>Fórmula:C21H22F2N6O2·H2O4SPureza:98.62% - 99.76%Cor e Forma:SolidPeso molecular:526.51Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Fórmula:C18H18FN5O2Pureza:99.92% - >99.99%Cor e Forma:SolidPeso molecular:355.377,8-Dihydroxyflavone
CAS:<p>7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.</p>Fórmula:C15H10O4Pureza:98.48% - 99.81%Cor e Forma:SolidPeso molecular:254.24Frunevetmab
CAS:<p>Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).</p>Pureza:95% - 95%Cor e Forma:LiquidFasinumab
CAS:<p>Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.</p>Pureza:95%Cor e Forma:LiquidFulranumab
CAS:<p>Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.</p>Pureza:95%Cor e Forma:LiquidTanezumab
CAS:<p>Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.</p>Pureza:95%Cor e Forma:LiquidBMS-754807
CAS:<p>BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.</p>Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49Protein kinase inhibitor 5
CAS:<p>Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, demonstrating an IC50 of 1.8 nM, and effectively suppresses cell viability [1].</p>Fórmula:C29H31F2N7OPureza:98%Cor e Forma:SolidPeso molecular:531.6Tavilermide
CAS:<p>Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.</p>Fórmula:C24H32N6O11Pureza:98.98%Cor e Forma:SolidPeso molecular:580.54TrkA-IN-1
CAS:<p>TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.</p>Fórmula:C25H20N4OPureza:98%Cor e Forma:SolidPeso molecular:392.45Paltimatrectinib
CAS:<p>Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.</p>Fórmula:C20H15F5N6Pureza:99.96%Cor e Forma:SolidPeso molecular:434.37CG 428
CAS:<p>CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM.</p>Fórmula:C43H43FN10O6Pureza:99.83%Cor e Forma:SolidPeso molecular:814.86Type II TRK inhibitor 1
CAS:<p>Type II TRK Inhibitor 1 is a potent inhibitor targeting multiple tropomyosin receptor kinase (TRK) fusion protein variants as well as the wild type.</p>Fórmula:C35H33F3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:670.68ENT-C225
CAS:<p>ENT-C225 is a potent TrkB neurotrophin receptor (TrkBR) activator with neuroprotective activity for the study of Alzheimer's disease and Parkinson's disease.</p>Fórmula:C26H40N4O5Pureza:99.36% - 99.36%Cor e Forma:SolidPeso molecular:488.62PF-06733804
CAS:<p>PF-06733804 is a potent inhibitor of pan-Trk in cell-based assays (IC50s: 8.4 nM, 6.2 nM, and 2.2 nM for TrkA, TrkB, and TrkC) with anti-hyperalgesic effect.</p>Fórmula:C20H19F5N4O4Pureza:98%Cor e Forma:SolidPeso molecular:474.38TRK-IN-24
CAS:<p>TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,</p>Fórmula:C39H45N7O3Pureza:98%Cor e Forma:SolidPeso molecular:659.82AZ-23
CAS:<p>AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.</p>Fórmula:C17H19ClFN7OPureza:99.4%Cor e Forma:SolidPeso molecular:391.83TRK-IN-28
CAS:<p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>Fórmula:C27H25F2N7Cor e Forma:SolidPeso molecular:485.53TRK-IN-26
CAS:<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Fórmula:C30H22F2N6O4Cor e Forma:SolidPeso molecular:568.53TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Fórmula:C16H13N3O3Cor e Forma:SolidPeso molecular:295.293TrkA-IN-8
CAS:<p>TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.</p>Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368
